Tamil Nadu’s Cough Syrup Tragedy: A Call for Accountability

Tamil Nadu’s Health Minister, Ma Subramanian, recently made headlines by revealing a startling fact: the Central Drugs Standard Control Organisation (CDSCO) hasn’t inspected drug manufacturing facilities in Tamil Nadu for a whopping six years. This shocking claim arises amid serious concerns following the deaths of 22 children after consuming a cough syrup called Coldrif, made by Sresan Pharmaceutical in Kanchipuram district.

CDSCO is the key body overseeing drug, medical device, and cosmetic regulations in India, directly under the Union Ministry of Health and Family Welfare. Minister Subramanian pointed out that it’s crucial for inspections to happen annually at all drug manufacturing units. Unfortunately, it seems that in Tamil Nadu, this hasn’t happened for years.

The tragic deaths of these children, who were taking Coldrif for common ailments like fever and cold, have raised alarm bells not just in Tamil Nadu but across India. Many were reported to have suffered severe reactions after taking the syrup, such as vomiting and difficulty in urination. The first unfortunate demise occurred on September 2, with several cases also reported in Rajasthan. Additionally, some children continue to receive critical care in Nagpur, Maharashtra.

In light of this, the authorities took immediate action. Two state drug inspectors were suspended for not ensuring proper quality checks on the syrup produced by Sresan Pharmaceutical. Minister Subramanian emphasized that central drug inspectors must inspect manufacturing facilities across India every three years. Yet, he stressed that nothing was done in Tamil Nadu during the previous six years. He asked a poignant question: “Where can we place the blame?”

Adding to the scrutiny, a report from the Comptroller and Auditor General highlighted significant shortfalls in drug inspections in Tamil Nadu, revealing an alarming inspection achievement rate of only 34% to 40% from 2016 to 2021. In response, Subramanian noted that the previous government, led by the All India Anna Dravida Munnetra Kazhagam (AIADMK), should be held accountable for these lapses.

After receiving alarming news from the Madhya Pradesh government on October 1 about potential contamination in Coldrif, Tamil Nadu’s Drugs Control Department launched an immediate inspection. The results were concerning; traces of diethylene glycol—a toxic substance—were found in the syrup. The presence of this chemical is particularly worrying since even a trace amount can be harmful. Diethylene glycol should ideally be completely absent in any syrup intended for consumption.

Due to these findings, on October 3, the state took decisive action by halting the production of Coldrif and issuing a show-cause notice to Sresan Pharmaceutical. The minister reassured the public that the state’s proactive efforts have helped prevent similar incidents in other states.

A significant response came from the Madhya Pradesh Chief Minister, Mohan Yadav, who accused the Tamil Nadu government of not cooperating with ongoing investigations surrounding the deaths of the children. Minister Subramanian countered this claim, stating that the owner of the pharmaceutical company was arrested as a direct result of Tamil Nadu’s thorough inspection and discovery of the syrup’s contamination.

Subramanian reiterated the importance of regular inspections in all 397 pharmaceutical manufacturing units in Tamil Nadu to ensure product safety. Meetings are underway between the Commissioner of Food Safety and Drug Administration, R Lalvena, and the inspectors to strengthen these efforts.

In reaction to the health risks posed by Coldrif, the Delhi government has since banned its sale, purchase, and distribution, echoing similar actions taken in several other states, including Kerala, Karnataka, and Uttar Pradesh. The concern over public health is paramount, and all stakeholders have been directed to cease sales of this potentially harmful product immediately.

The situation calls for a broader discussion about drug safety regulations in India and emphasizes the need for accountability from regulatory agencies. As citizens, we must remain vigilant and advocate for our safety and well-being.

As we witness these unfortunate events, let’s unite in hoping for swift and effective reforms in drug inspections and safety regulations across the country to protect our children and ensure no such tragedy occurs again.

HealthSafety #DrugRegulations #TamilNadu #CoughSyrupScandal

Original Text – https://scroll.in/latest/1087536/central-drugs-standard-body-did-not-carry-out-inspections-in-tamil-nadu-for-6-years-claims-minister?utm_source=rss&utm_medium=public